文献速递急性肾损伤慢性肾脏病

急性肾损伤向慢性肾脏病转化过程中蛋白酶激活受体-1缺失对肾小管血管的保护作用

Tubulovascular protection from protease-activated receptor-1 depletion during AKI-to-CKD transition.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

本研究利用单侧缺血再灌注损伤诱导慢性肾脏病的小鼠模型,探讨蛋白酶激活受体-1(PAR-1)在急性肾损伤向慢性肾脏病转化中的肾小管血管交互机制。结果显示PAR-1缺失可减轻早期肾脏炎症、血管损伤并保护内皮完整性和毛细血管通透性,在转化期保护肾功能并通过下调转化生长因子-β/Smad信号减少肾小管间质纤维化。在凝血酶诱导的人真皮微血管内皮细胞中,PAR-1通过激活NF-κB和ERK MAPK通路介导血管损伤;药物阻断PAR-1可改善肾脏形态、促进血管再生能力并减少炎症和纤维化,效果取决于开始给药的时间。

要点

  • PAR-1缺失在急性肾损伤早期减轻肾脏炎症、血管损伤并保护内皮完整性和毛细血管通透性。
  • PAR-1缺失在向慢性肾脏病转化期保护肾功能并通过下调TGF-β/Smad信号减少肾小管间质纤维化。
  • 药物阻断PAR-1可改善肾脏形态、促进血管再生能力并减少炎症和纤维化,效果取决于开始给药的时间。

核心结论

  • PAR-1在急性肾损伤向慢性肾脏病转化过程中对组织损伤后的血管功能障碍和促纤维化反应起不利作用, PAR-1阻断可能为急性肾损伤后修复提供有吸引力的治疗策略。

研究设计与样本

  • 采用单侧缺血再灌注损伤诱导慢性肾脏病的小鼠动物模型,探讨PAR-1在急性肾损伤向慢性肾脏病转化中的肾小管血管交互机制。
  • 在凝血酶诱导的人真皮微血管内皮细胞(HDMECs)中进行体外实验,包括PAR-1基因沉默。

主要发现

  • 急性肾损伤早期,PAR-1缺陷小鼠肾脏炎症减轻、血管损伤减少,内皮完整性和毛细血管通透性得以保持。
  • 向慢性肾脏病转化期,PAR-1缺陷通过下调转化生长因子-β/Smad信号保护肾功能并减少肾小管间质纤维化。
  • 急性肾损伤后微血管适应不良性修复加重局灶性缺氧和毛细血管稀疏,PAR-1缺陷小鼠通过稳定缺氧诱导因子和增加肾小管血管内皮生长因子A得以改善。
  • PAR-1缺陷小鼠慢性炎症也被阻止,肾脏M1型和M2型极化巨噬细胞浸润均减少。
  • 在凝血酶诱导的HDMECs中,PAR-1通过激活NF-κB和ERK MAPK通路介导血管损伤;PAR-1基因沉默在缺氧下通过肾小管血管交互机制发挥微血管保护作用。

临床怎么用

  • 作者认为PAR-1阻断可能为急性肾损伤后修复提供有吸引力的治疗策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thromboembolic events are prevalent in chronic kidney disease (CKD) patients due to increased thrombin generation leading to a hypercoagulable state. We previously demonstrated that inhibition of protease-activated receptor-1 (PAR-1) by vorapaxar reduces kidney fibrosis. METHODS: We used an animal model of unilateral ischemia-reperfusion injury-induced CKD to explore the tubulovascular crosstalk mechanisms of PAR-1 in acute kidney injury (AKI)-to-CKD transition. RESULTS: During the early phase of AKI, PAR-1-deficient mice exhibited reduced kidney inflammation, vascular injury, and preserved endothelial integrity and capillary permeability. During the transition phase to CKD, PAR-1 deficiency preserved kidney function and diminished tubulointerstitial fibrosis via downregulated transforming growth factor-β/Smad signaling. Maladaptive repair in the microvasculature after AKI further exacerbated focal hypoxia with capillary rarefaction, which was rescued by stabilization of hypoxia-inducible factor and increased tubular vascular endothelial growth factor A in PAR-1-deficient mice. Chronic inflammation was also prevented with reduced kidney infiltration by both M1- and M2-polarized macrophages. In thrombin-induced human dermal microvascular endothelial cells (HDMECs), PAR-1 mediated vascular injury through activation of NF-κB and ERK MAPK pathways. Gene silencing of PAR-1 exerted microvascular protection via a tubulovascular crosstalk mechanism during hypoxia in HDMECs. Finally, pharmacologic blockade of PAR-1 with vorapaxar improved kidney morphology, promoted vascular regenerative capacity, and reduced inflammation and fibrosis depending on the time of initiation. CONCLUSIONS: Our findings elucidate a detrimental role of PAR-1 in vascular dysfunction and profibrotic responses upon tissue injury during AKI-to-CKD transition and provide an attractive therapeutic strategy for post-injury repair in AKI.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Lok SWY, Yiu WH, Zou Y, et al. Tubulovascular protection from protease-activated receptor-1 depletion during AKI-to-CKD transition. Nephrol Dial Transplant. 2023. PMID: 36914214. doi:10.1093/ndt/gfad051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。